RADLY:OTO-Raia Drogasil SA ADR (Sponsored) (USD)

COMMON STOCK | Pharmaceutical Retailers | OTC Pink

Last Closing

USD 3.11

Change

-0.51 (-14.09)%

Market Cap

USD 6.31B

Volume

8.90K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Raia Drogasil SA is a retail drugstore chain in Brazil. The Company engages in retail sales of medications, perfumery, personal care and beauty products, cosmetics and dermocosmetics and specialty medicines.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Pharmaceutical Retailers

Symbol Name Price(Change) Market Cap
JDHIY JD Health International Inc

N/A

USD 12.19B
JDHIF JD Health International Inc

N/A

USD 10.00B
ALBHF Alibaba Health Information Tec..

+0.01 (+1.14%)

USD 8.29B
CLCGY Clicks Group Ltd

-1.88 (-4.56%)

USD 5.27B
SHPPF Shop Apotheke Europe N.V

N/A

USD 3.20B
SAEYY Shop Apotheke Europe N.V

N/A

USD 2.88B
NOTR Nowtransit Inc

N/A

USD 0.55B
ZRSEF Zur Rose Group AG

N/A

USD 0.46B
PNPL Pineapple Express

N/A

USD 0.01B
RLLVF Relevium Technologies Inc

N/A

USD 5.33M

ETFs Containing RADLY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Pharmaceutical Retailers) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -56.81% 27% F 18% F
Dividend Return 0.58% 50% F 4% F
Total Return -56.22% 27% F 18% F
Trailing 12 Months  
Capital Gain -53.58% 36% F 20% F
Dividend Return 0.78% 50% F 6% D-
Total Return -52.81% 36% F 19% F
Trailing 5 Years  
Capital Gain -40.65% 79% B- 43% F
Dividend Return 4.29% 50% F 10% F
Total Return -36.36% 79% B- 41% F
Average Annual (5 Year Horizon)  
Capital Gain 6.02% 50% F 47% F
Dividend Return 6.79% 46% F 45% F
Total Return 0.77% 50% F 24% F
Risk Return Profile  
Volatility (Standard Deviation) 45.16% 75% C 55% F
Risk Adjusted Return 15.04% 50% F 47% F
Market Capitalization 6.31B 85% B 88% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.